Evidence map›Paper›PMID 29572645›Full record

ArticleNeurochemical research2018

Effects of the Serotonin 5-HT

Adrian Newman-Tancredi, Mark A Varney, Andrew C McCreary

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Adrian Newman-TancrediNeurolixis Inc., 34145 Pacific Coast Highway #504, Dana Point, CA, 92629, USA. anewmantancredi@neurolixis.com.ORCID http://orcid.org/0000-0002-2923-5714
Mark A VarneyNeurolixis Inc., 34145 Pacific Coast Highway #504, Dana Point, CA, 92629, USA.
Andrew C McCrearyBrains On-Line BV, De Mudden 16, Groningen, 9747 AW, The Netherlands.
Neurolixis (United States) · USWolters Kluwer (Netherlands) · NL

Funding

Michael J. Fox Foundation for Parkinson's Research Research Grant
6 · The paper itself

Abstract

Peak-dose dyskinesia is associated with the dramatic increase in striatal dopamine levels that follows L-DOPA administration. The 'false neurotransmitter' hypothesis postulates that the latter is likely due to an aberrant processing of L-DOPA by serotonergic neurons. In keeping with this hypothesis, two highly selective 'biased agonists' of 5-HT

Indexed as

AminopyridinesAnimalsAnti-Dyskinesia AgentsAntiparkinson AgentsDose-Response Relationship, DrugGlutamic AcidLevodopaMaleNeostriatumNeurotransmitter AgentsParkinson Disease, SecondaryPiperidinesPyrimidinesRatsRats, Sprague-DawleyReceptor, Serotonin, 5-HT1A3-chloro-4-fluorophenyl-(4-fluoro-4-(((5-methyl-6-methylaminopyridin-2-ylmethyl)amino)methyl)piperidin-1-yl)methanone3-chloro-4-fluorophenyl-(4-fluoro-4-(((5-methylpyrimidin-2-ylmethyl)amino)methyl)piperidin-1-yl)methanoneAminopyridinesAnti-Dyskinesia AgentsAntiparkinson AgentsGlutamic AcidLevodopaNeurotransmitter AgentsPiperidinesPyrimidinesReceptor, Serotonin, 5-HT1ASerotoninSerotonin 5-HT1 Receptor Agonists5-HT1A receptorsDopamineDyskinesiaGlutamateParkinson’s diseaseSerotonin

Identifiers

PMID29572645
OpenAlexW2793487590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.